Challenges on the epidemiological and economic burden of diabetes and hypertension in Mexico

Armando Arredondo, Emanuel Orozco, Jaqueline Alcalde-Rabanal, Juan Navarro, Alejandra Azar

Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil

ABSTRACT

OBJECTIVE: To analyze the epidemiological and economic burden of the health services demand due to diabetes and hypertension in Mexico.

METHODS: Evaluation study based on a time series study that had as a universe of study the assured and uninsured population that demands health services from the three main institutions of the Health System in Mexico: The Health Department, the Mexican Institute of Social Security, and Institute of Services and Social Security for State Workers. The financing method was based on instrumentation and consensus techniques for medium case management. In order to estimate the epidemiological changes and financial requirements, a time series of observed cases for diabetes and hypertension 1994–2013 was integrated. Probabilistic models were developed based on the Box-Jenkins technique for the period of 2013–2018 with 95% confidence intervals and p < 0.05.

RESULTS: Comparing results from 2013 versus 2018, in the five regions, different incremental trends of 14%–17% in epidemiological changes and 58%-66% in the economic burden for both diseases were observed.

CONCLUSIONS: If the risk factors and the different models of care remained as they currently are in the three institutions analyzed, the financial consequences would be of greater impact for the Mexican Institute of Social Security, following in order of importance the Institute of Services and Social Security for State Workers and lastly the Health Department. The financial needs for both diseases will represent approximately 13%–15% of the total budget allocated to the uninsured population and 15%–17% for the population insured depending on the region.

DESCRIPTORS: Diabetes Mellitus, epidemiology. Hypertension, epidemiology. Health Services Needs and Demand, economics. Healthcare Financing.
INTRODUCTION

Within the framework of effective universal coverage, the increase in the costs of health services for the treatment of noncommunicable diseases, the need to increase investment, the lack of financial protection of the health services user, and the urgency of changes in the methods of resources distribution in the health sector have aroused multiple concerns among decision makers. The demand for health care does not diminish and the high cost of the different alternatives of action in this period of transitions in all areas imposes a heavy burden on the national and state budgets that governments are trying to reduce.

Cardiovascular diseases in people with diabetes mellitus begin earlier, and present with atypical symptoms and signs. The complications of chronic diseases such as diabetes and hypertension increase significantly. The investment of health systems to treat diabetes should include not only the management of the disease but also its complications. Diabetes is a worldwide emergency due to excessive spending that affects the sustainability of health systems. Complications of noncommunicable diseases are costly: diabetic nephropathy has been shown to be the most costly complication of diabetes in the Americas.

In economic terms, the significance of the changes in the epidemiological and demographic profile is an increase in the care demand for costly diseases (treatment of chronic degenerative diseases and accidents). This will compete with the budget allocated for the treatment of infectious diseases still unresolved. Thus, there will be a need to develop and apply analytical tools to reassess health priorities and establish strategic actions for the allocation, use and adequate organization of financial resources in the health sector.

This article aimed to analyze the epidemiological and economic burden of the health services demand due to diabetes and hypertension in Mexico. We analyzed the epidemiological changes expected for the period of 2013–2018, as well as the financial requirements for the two study demands at the Mexican Social Security Institute (IMSS), the Health Department (SSA) and the Institute of Services and Social Security for State Workers (ISSSTETE) at the level of each state health system.

METHODS

Evaluation research based on a time series study in Mexico for the period of 2013–2018. The selected states were Jalisco, Hidalgo, Morelos, Sinaloa, and Yucatan. The states studied showed relative heterogeneity for the indicators of marginalization, public insurance, epidemiological delay and original population index, in the macroeconomic indicators of socioeconomic development. The indexes of epidemiological delays and original population represented greater challenges in all cases since the highest index of marginalization coincided with the highest epidemiological delay, which is usually more urgent in the original population.
Study institutions included IMSS, SSA, and ISSSTE. The annual demand for health services for hypertension and diabetes was obtained from the number of cases in control for diabetes and hypertension reported by type of institution. This information was obtained from the statistics bulletin on health damages of the National Health System, 1994–2013.12

The direct costs of care were obtained from standard case management and adjusted by type of institution. The financing method was based on the methodology of related diagnostic groups (GRD [Group of Related Diagnostic] variant adjusted for Mexico)13 and based on the instrumentation technique. Once the work teams were integrated and the diseases to be covered (diabetes and hypertension) had been selected, we chose to work with the consensus technique to determine the mean case management. In order to do this, we discussed the pilot test, the collection instruments that, according to the natural history of the disease and the work experience of the multidisciplinary team, were redesigned to capture the different processes, procedures and resources (production functions and materials), as well as all ex-ante and ex-post activities of each production function to provide the service that each pathology requires. The participation of physicians was fundamental for determining the different medical care processes and for the fact that the quality of care offered at the hospital and at different levels of care was debated from the perspective of the provider.

The data collection instruments for each production function included different categories of material and cost analysis: infrastructure, human resources in medical hours, nurse hours and administrative hours, laboratory studies, complementary studies, average stay-day-bed, components of drug-curative therapy, intensive care components, contracted services, general services, other resources, processes and procedures, and observations. The materials and costs were concentrated in financing matrices by type of illness and type of institution.

This technique was used to establish consensus and standardize the methodology for obtaining production functions and materials. The professionals of the different areas (clinical, epidemiological and administrative) had an active and determinant participation in the management of the mean case by illness. Every member of the work team had at least five years of clinical-administrative practice experience.

To determine the financial requirements of expected cases, a time series 1994–2013 was carried out. Autoregression models were designed using the Stat Graphics software under the Box-Jenkins technique14 and with 95% confidence intervals and p < 0.05. The proposed method was justified because the case observations showed to be highly correlated. This is because we have available data recorded for diabetes and hypertension with the quality and quantity required to apply this technique. In addition, it is one of the most recommended methods for medium- and long-term projections in the analysis of chronic public health problems. The development of the models considered each of the following methodological steps and phases:

**Step 1: Identification**
- Identification of the tentative model of the time series for use in prediction.
- Review of information quality and number of observations for diabetes and hypertension.
- Self-correlation analysis of historical observations.

**Step 2: Estimate**
- Determination of parameter estimators, using the least squares criterion.
- Application of an iterative procedure to search for a function of the sum of squares, specifying previously the preliminary estimators of the unknown parameters.

**Step 3: Verification of diagnosis**
- Proof of suitability, after the models are adjusted to the data.
• Analysis of the difference between the observed and the expected in cases of diabetes and hypertension.

• Application of the Box-Pierce chi-squared.

**Step 4: Prediction**

• Selection and design of the definitive model.

• Data processing.

• Prediction of definitive expected values for the time series, both in diabetes and in hypertension

The selection of models and prediction equations were designed with cases observed up to 2012. Once a results report was prepared, it was ratified to update the projections with the cases observed until December 2012, projecting for the period of 2013–2018. These results were used to analyze the financial implications of epidemiological changes for hypertension and diabetes in each institution and the state health system under study.

To estimate the financial consequences of changes in demands by type of institution and disease, an inflation index projected for 2013–2018 was applied, based on the Bank of Mexico consumer price index\(^\text{15}\). The results were presented in National Currency and US dollars at the exchange rate in June 2015 and with an exchange rate of US $1 = Mex $14.35.

**RESULTS**

The results for the case of diabetes and hypertension were similar in the model development except in the number of cases per type of disease, as will be verified later.

The historical data were the number of monthly cases of diabetes in the period from 1996 to 2012. Monthly case numbers were denoted by \(Y_1, Y_2, \ldots, Y_{84}\). The number of cases followed a pattern with a strong upward trend until the year 2000, declining sharply in 2001 and increasing again in 2002, with irregular peaks until 2012. The slope coefficient in trend analysis was positive and significantly different from zero \((t = 6.76)\). The time series was described by the trend factor and the number of cases of diabetes tended to increase.

On the autocorrelation function of the original series, the series was not stationary, because the autocorrelation function slowly declined. After applying the transformation of a non-seasonal difference, the time series seems to be stationary and can be explained by the transformation \(Z_t = Y_t - Y_{t-1}\) which means a non-seasonal difference.

It seems that the autocorrelation function intersects the line representing the boundary of non-zero statistical significance after lag 1 and that the partial autocorrelation function dies quickly. This indicates the need to include an average order operator of order 1. Another interpretation of both functions is that the autocorrelation function dies quickly and that the partial autocorrelation function is cut in lag 1. Thus, the time series could be explained by an autoregressive operator of order 1.

As a result of the analysis of the functions of autocorrelation and partial autocorrelation, the following models were proposed:

Model 1 – Medium movement operator of order 1:

\[
Z_t = \delta + e_t - \theta_t e_{t-1}
\]

Model 2 – Autoregressive operator of order 1:

\[
Z_t = \delta + \phi_t Z_{t-1}
\]
The results of the two models were presented in Table 1. We included the parameter estimators in each model, the t-statistic, the Box-Pierce chi-squared statistic in the first 20 residuals, and we indicated the lags in which the residuals had significantly different non-zero correlations. The standard separation value (s) was presented for each model. The two models fit the data well and did not have self-correlations of residuals significantly different from zero. Model 2 was selected as the definitive model because it was the one with the lowest standard error (Table 2).

With the results of this adjustment, it was demonstrated that the autoregressive operator of order 1 adequately described the cases of diabetes mellitus, since the difference between observed and estimated was small. As the slope value of the series resulted significantly different from zero \((t = 6.76)\), a constant term was used when adjusting the model. This coincides with the judgments of the health planners, who consider that chronic illnesses tend to increase, that is, that the rate of increase tendency will continue in the future in the short, medium and long-term. For this reason, both models included this term. The appropriate model was Model 2, with the prediction equation.

\[
\gamma_t = \delta + \gamma_{t-13} + \beta_{1,12} e_{t-13} - \theta_1 e_{t-1} + \theta_1 \theta_{1,12} e_{t-13} + \epsilon_t
\]

Where:

- \(\gamma_t\) = The annual average of expected cases
- \(\delta\) = Partial autocorrelation residual factor
- \(\gamma_{t-13}\) = The historical value of the series of years prior to prediction
- \(\beta_{1,12} e_{t-13}\) = Partial autocorrelation coefficient of the time series
- \(\theta_1 e_{t-1}\) = Number of cases per type of estimator (A, B or C)
- \(\theta_1 \theta_{1,12} e_{t-13}\) = Average value of the series by total autocorrelation
- \(\epsilon_t\) = The critical value of the standard deviation

In all the states, we observed epidemiological trends of observed and expected cases for constant increasing diabetes and hypertension, with irregular peaks before 2012, especially in Jalisco, where the greatest epidemiological burden was observed in absolute terms (Table 3). The difference in diabetes, in the case of hypertension, the first place in terms of the number of cases, were shared by Jalisco and Sinaloa. Morelos, Yucatan, and Hidalgo presented constant trends, slightly increasing and without irregular peaks. The irregular trends were found more in the case of Jalisco and Sinaloa for the first part of the period.

Constant growing trends in financial requirements were observed in all states. The increases occurred in a space between 8% and 40% depending on the year of analysis and the state.

| Table 2. Results of statistical proofs of estimative models of diabetes and hypertension cases. Cuernavaca, 2016. |
|-----------------------------------------------|------------------|------------------|
| Variable | Model 1 | Model 2 |
|-----------------|--------|--------|
| Number of non-stationary differences | 1 | 1 |
| Number of stationary differences | 0 | 0 |
| Number of parameters | 3 | 2 |
| Estimator A | 0.7689 (4.01) | 0.2579 (2.43) |
| Estimator B | 0.5536 (2.23) | -0.2723 (-2.54) |
| Estimator C | 0.9123 | 0.8599 |
| Box-Pierce chi-squared | 14.67 | 22.25 |
| Standard deviation | 26.9 | 21.22 |
| Correlations other than zero | 0 | 0 |
The state that presented the greatest financial requirements was Jalisco, followed by Sinaloa, Morelos, Hidalgo and lastly Yucatan, with an economic burden almost half of the penultimate state (Hidalgo). Comparing the state of greater economic burden (Jalisco) with the state of lower economic burden (Yucatan), the difference was more or less five to one.

The largest economic burden was presented by the IMSS, followed by the SSA and lastly the ISSSTE. The results detailing the costs and financial consequences attributable to hypertension appear in the attachment tables. It is important to note that the three institutions presented constant increasing trends for each of the years of the estimation period.

Differently from the economic burden of diabetes, hypertension presented the highest economic burden for the case in Sinaloa followed by Jalisco, Morelos, Hidalgo, and Yucatan in descending order. Comparing the spaces of economic impact by state, with Sinaloa as high impact and Yucatán as sub impact, the difference was more or less three to one. The trends of increases were similar to those of Diabetes in a space between 8.0% and 40.0% depending on the period of analysis.

Economic and epidemiological trends can be graphically observed in the period between 2012-2018 (Figures 1–4). For the diabetes case, the difference between the five states was evident, as well as the absence of irregular periods without overlap between the states. The order of importance was: Jalisco, Sinaloa, Morelos, Hidalgo, and Yucatan.

We noted the difference in the trend of combination of epidemiological and economic burden for diabetes mentioned at the beginning against the trend in prevalence rates. In fact, while in the combination of epidemiological trends and economic burden the first place was occupied by Jalisco, followed by Sinaloa, Morelos, Hidalgo, and Yucatan in decreasing

---

Table 3. Number of cases expected by type of disease at the state level (cases in absolute value). Cuernavaca, 2013–2018.

| Disease/State | Number of cases per year | P      |
|--------------|--------------------------|--------|
|              | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| Diabetes     |      |      |      |      |      |      |
| Sinaloa      | 16,126 | 15,524 | 17,457 | 16,677 | 18,270 | 18,496 | < 0.01 |
| 95%CI*       | 15,926–16,326 | 15,114–15,934 | 16,937–17,977 | 15,997–17,357 | 17,530–19,010 | 17,646–19,346 | < 0.01 |
| Morelos      | 10,618 | 10,803 | 11,660 | 11,982 | 12,681 | 12,975 | < 0.01 |
| 95%CI*       | 10,418–10,818 | 10,393–11,213 | 11,140–12,180 | 11,302–12,662 | 11,941–13,421 | 12,125–13,825 | < 0.01 |
| Hidalgo      | 9,232 | 9,605 | 9,864 | 10,355 | 10,666 | 11,124 | < 0.01 |
| 95%CI*       | 9,032–9,432 | 9,192–10,015 | 9,344–10,384 | 9,675–11,035 | 9,946–11,426 | 10,274–11,974 | < 0.01 |
| Jalisco      | 19,154 | 20,794 | 21,454 | 21,996 | 22,352 | 22,666 | < 0.01 |
| 95%CI*       | 18,954–19,354 | 20,384–21,204 | 20,934–21,974 | 21,316–22,676 | 21,612–23,092 | 21,816–23,516 | < 0.01 |
| Yucatan      | 6,174 | 6,409 | 6,382 | 6,700 | 6,980 | 7,172 | < 0.01 |
| 95%CI*       | 5,974–6,374 | 5,999–6,819 | 5,862–6,902 | 6,020–7,380 | 6,240–7,720 | 6,322–8,022 | < 0.01 |
| Hypertension |      |      |      |      |      |      |
| Sinaloa      | 28,017 | 29,673 | 31,406 | 33,018 | 34,308 | 35,424 | < 0.01 |
| 95%CI*       | 27,817–28,217 | 29,263–30,083 | 30,886–31,926 | 32,338–33,698 | 33,563–35,043 | 34,574–33,274 | < 0.01 |
| Morelos      | 15,353 | 15,645 | 16,010 | 16,196 | 17,392 | 17,619 | < 0.01 |
| 95%CI*       | 15,153–15,553 | 15,235–16,055 | 15,490–16,530 | 15,516–16,876 | 16,652–18,132 | 16,769–18,469 | < 0.01 |
| Hidalgo      | 9,992 | 10,246 | 10,422 | 11,107 | 11,441 | 11,748 | < 0.01 |
| 95%CI*       | 9,792–10,192 | 9,836–10,656 | 9,902–10,942 | 10,427–11,787 | 10,701–12,181 | 10,898–12,598 | < 0.01 |
| Jalisco      | 26,982 | 30,851 | 31,169 | 31,658 | 32,116 | 32,477 | < 0.01 |
| 95%CI*       | 26,782–27,182 | 30,441–31,261 | 30,649–31,689 | 30,978–32,338 | 31,376–32,856 | 31,627–33,327 | < 0.01 |
| Yucatan      | 8,953 | 9,222 | 9,465 | 9,620 | 9,785 | 10,022 | < 0.01 |
| 95%CI*       | 8,753–9,153 | 8,812–9,632 | 8,945–9,985 | 9,840–10,300 | 9,045–10,525 | 9,172–10,872 | < 0.01 |

* 95% confidence intervals with Box-Pierce statistical test.
order, in the case of prevalence, the first place was occupied by Yucatan, followed by Hidalgo, Sinaloa, Morelos and Jalisco. The trend in the states was totally reversed so that Yucatan ranked first and Jalisco last in order of importance in the impact.

For the hypertension case, while in the combination of the epidemiological and economic burden the greatest impact was for Sinaloa and Jalisco, followed by Yucatan, Hidalgo, and Morelos in decreasing order, in the case of an impact by prevalence there are similarities in trends. In fact, the highest prevalence was for Sinaloa followed by Hidalgo, Jalisco, Yucatan and Morelos in descending order. In both analyzes, the major and minor impact trends were for Sinaloa and Morelos, respectively.

Exchange rate of 14.35 MEX $ per 1 US $ (Reference period June 2015).

**Figure 1.** Total costs of diabetes in different states (in US$). Cuernavaca, 2012–2018.

Exchange rate of 14.35 MEX $ per 1 US $ (Reference period June 2015).

**Figure 2.** Total costs of hypertension in different states (in US$). Cuernavaca, 2012–2018.
Diabetes and hypertension in Mexico Arredondo A et al.

DISCUSSION

The trends of our findings in terms of epidemiological trends and economic impact coincide in important ways with other studies or similar analyzes\textsuperscript{16–20}. Their analyzes coincide in the need to incorporate the economic evaluation within the health sector and to organize with greater efficiency the production of services prioritizing according to the real needs of the population that will make use of it. The trends of constant increases are justified by a number of reasons: the diversification of the demand for pressures in expected epidemiological exchanges, the scarcity of financial resources, and the varied and endless health needs that will be generated with the important changes in the epidemiological profile for the coming years in the majority of developing countries, especially in Latin America\textsuperscript{21,22}.

The change in epidemiological profiles and the consequent increase in the demand for resources to treat these chronic diseases strongly suggest the need to adjust the care model...
so that cases are increasingly treated on an outpatient basis. The objective is to reduce the emergence of complications that require hospital management. An essential feature of the adjusted model would be to increase the value of outpatient care for the patient. This objective is in clear relation with the economic rationality of efficiency, just as it has resulted in similar studies of health costs for chronic diseases.17,23

Insurance systems are financed with public resources from taxes. Given the global economic crisis and its effects on health,24 health budgets, particularly for Mexico and most Latin American countries, have declined significantly in recent years.25 More than ever, efficient institutions are needed to allocate and manage resources. Likewise, it is required that the efficient use of resources guarantee the financial feasibility of strategies that minimize the costs of care linked to chronic diseases, that is, to direct resources to basically preventive and health promotion actions. In this sense, diabetes and hypertension need the implementation of care models oriented to the empowerment and active participation of users so that self-care favors the identification of complications in advance. These models that involve the patient and their family in the health care are highly effective because they can report in advance the emergence of a complication. Consequently, complications can be greatly reduced. This will have favorable consequences for the reduction or greater control of the costs of care related to these ailments and their complications. It is necessary to strengthen the first level of care to promote and strengthen a model focused on prevention and health promotion.

The results of our study show the relevance of incorporating epidemiological and economic aspects into the clinical perspective, periodically, the integral proposal for the analysis and evaluation of the performance of the health system in the context of sector reforms. The development of evaluation research studies that integrate an economic valuation with clinical and epidemiological valuations becomes relevant based on empirical expectations. As health reform projects proceed, the cost of lending services solely to the demand for hospital cases of chronic-degenerative diseases will be higher relative to the cost of providing service to the demand for outpatient and hospital cases of infectious diseases. This implies that the further advancement of the epidemiological transition will have greater financial consequences in the production of medical care services for future demands on diseases such as diabetes and hypertension.

The changes observed and expected in the epidemiological profile of chronic diseases in relation to infectious diseases will lead to a financial competence in the use of resources. The allocation of financial resources to produce services aimed at chronic diseases will be affected by the production of services for infectious diseases. Internal competence in the use and allocation of economic resources requires the approximate knowledge of the financial requirements to produce the services that will be demanded in the short and medium term. In this sense, the production and financing of health services will require incorporating clinical, epidemiological and economic indicators integrating these indicators under the criterion of efficiency depending on the context of each state's health system.

The results allow us to make significant changes in the allocation of resources and adjustments to the model of care of the state's health systems in function of the variables of epidemiological backwardness, relative weight of the indigenous communities, incorporation of cultural aspects in proposals of prevention and promotion models taking in consideration habits and customs in each region. This differential analysis will have important effects on the phenomenon of internal competence in the use and allocation of resources in different scenarios. For example, in Jalisco and Sinaloa, higher increasing trends of diabetes and hypertension were observed than in the rest of the states included in the study. This leads us to infer unequal growth trends in diabetes and hypertension in the states and that supposes three scenarios: states with high growth (Jalisco and Sinaloa), states with medium growth (Yucatan) and states with low growth (Hidalgo and Morelos). These scenarios will require research to explain the factors that influence the lower or higher growth of chronic diseases and support to implement integrated strategies in a care model that can curb the growth of this type of ailments.
The main limitation in time series studies refers to the availability of quality and quantity data in the number of observations. However, there was an adequate number of observations in this study to be able to make the estimates with a high degree of reliability. As we move to the last year of the period, both the epidemiological and economic burdens may have less precision and certainty; so we recommend a monitoring to update the time series and their respective epidemiological and economic burden at least every two years. Another limitation is that the estimated economic burden may vary as there are changes in medical technology and drugs to manage both diseases, possible changes to the protocol or possible changes to health programs, or by inflationary changes in the price index of materials. There is hope that these changes will not happen in five-year periods, and bi-annual monitoring could control these constraints.

In terms of relative frequencies, at national, state/provincial or institutional levels (institutions for insured persons and institutions for public assistance), the analysis of expected levels and epidemiological and economic trends can be replicated. The same trend of relative frequencies can be applied to the analysis of other chronic diseases of any country with epidemiological changes similar to Mexico since the diseases of the study were selected under the criterion of idealizers of the epidemiological transition. It can also be applied to other levels of intervention, diseases or other institutions of the health sector as the relative frequencies that correspond to each production function on the cost of handling interventions.

The changes in the epidemiological profile of Latin American countries raise doubts that one of the biggest challenges is the economic one. Both the internal competence and the patterns of resource allocation will be directly affected by the expected epidemiological changes. The costs of providing services aimed at new and more demanding chronic diseases, as well as competing with the classic demands of infectious diseases, require important changes in the patterns of resource allocation. The costs and financial consequences of the change in the epidemiological profile are analytical elements that should be taken into account in the planning of current and future health plans or programs at regional, national and state/state level, even if health sector spending is increased, especially when talking about the restructuring of public spending that raised doubts for the next years in each national and/or state health system.

REFERENCES

1. Cercone J. Asociación público-privada para la atención a la salud: el desafío de la reforma en salud. In: Foro de Europa y América sobre las Reformas del Sector Salud. Santiago de Chile: Banco Mundial; 2002. p.6-11.

2. Gaziano TA. Chronic disease management in Latin America and Caribbean: Washington (DC): Inter-American Development Bank; 2011. p.54-68. Background paper prepared for RG-K1041 Prevention and Management of Chronic Disease.

3. Wodon QT, Ayres R, Barenstein M, Hicks N, Lee K, Maloney W, et al. Poverty and policy in Latin America and the Caribbean. Washington (DC): The World Bank; 2000 [citado 30 sept 2017], (World Bank Technical Paper, 467). Disponible en: http://documents.worldbank.org/curated/en/536291468774256064/Poverty-and-policy-in-Latin-America-and-the-Caribbean

4. Glassman A, Gaziano TA, Bouillon Buendia CP, Guanais de Aguiar FC. Confronting the chronic disease burden in Latin America and the Caribbean. Health Aff (Millwood). 2010;29(12):2142-8. https://doi.org/10.1377/hlthaff.2010.1038

5. World Health Organization. Guidelines to assess the social and economic impact consequences of the diseases. Geneva: WHO; 2009. p.37-56.

6. Arredondo A, Reyes G. Health disparities from economic burden of diabetes in middle-income countries: evidence from México. Plos ONE. 2013;8(7):e68443. https://doi.org/10.1371/journal.pone.0068443

7. Elliot WJ. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med. 1996;99(4):241-8, 251-2.

8. Snowdon A, Schnarr K, Hussein A, Alessi C. Measuring what matters: the cost vs. values of health care. London (CA): International Centre for Health Innovation; 2012 [citado 30 sept 2017]. p.12-20. Disponible en: http://sites.ivey.ca/healthinnovation/files/2012/11/White-Paper-Measuring-What-Matters.pdf
9. Johnson S, Delate T, Boka A, Shaw P, Zager C. Characterizing the financial burden of pulmonary arterial hypertension within an integrated healthcare delivery system. *J Med Econ*. 2013;16(12):1414-22. https://doi.org/10.11606/S1518-8787.2013.849713

10. Secretaría de Salud (MEX). Encuesta Nacional Salud y Nutrición: Diabetes. 3.ed. México (DF): SSA; 2015. p.186-91.

11. Consejo Nacional de Población; Instituto Nacional de Estadística y Geografía. Censo de Población 2010-2015: indicadores sociodemográficos por estado. México (DF): CONAPO; 2015.

12. Secretaría de Salud (MEX); Instituto Mexicano do Seguro Social; Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Casos de morbilidad hospitalaria por demanda específica, 1996-2013. *Bol Int Estad*. 2014:57-81.

13. Arredondo A. Type 2 diabetes and health care costs in Latin America: exploring the need for greater preventive medicine. *BMC Med*. 2014;12:136. https://doi.org/10.1186/s12916-014-0136-z

14. Aitikin M. Statistical modelling and statistical inference: measurement error in the explanatory variables. Box-Jenkins technique. In: Aitikin M, Francis B, Hinde J. Statistical modelling in GLIM 4. 2.ed. New York: Oxford University Press; 2005. Chapter 2; Statistical modelling and statistical inference: measurement error in the explanatory variables. Box-Jenkins technique; p.112-32.

15. Banco de México. Indice Nacional de Precios por Servicios Médicos en México: Base 2000=100: la actividad económica en México: 1992-2014. México (DF): BM Gerencia de Investigación Económica; 2015. p.36-49. (Cuadernos Mensuales).

16. Canadian Diabetes Association. An economic tsunami: the cost of diabetes in Canada. Toronto; 2009 [citado 30 sept 2017]. Disponible en: https://www.diabetes.ca/CDA/media/documents/publications-and-newsletters/advocacy-reports/economic-tsunami-cost-of-diabetes-in-canada-english.pdf

17. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. *Diabetes Care*. 2013;36(4):1033-46. https://doi.org/0.2337/dc12-2625

18. International Diabetes Federation. Diabetes Atlas 2015: executive summary. 7. ed. Brussels: IDF; 2015.

19. Barceló A, Aedo C, Rajipathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. *Bull World Health Organ*. 2003;81(1):19-27. https://doi.org/10.1590/S0042-96862003000100006

20. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. *Diabetes Res Clin Pract*. 2010;87(3):293-301. https://doi.org/10.1016/j.diabres.2010.01.026

21. Santos JC, Moreira TMM. Risk factors and complications in patients with hypertension/diabetes in a regional health district of northeast Brazil. *Rev Esc Enferm USP*. 2012;46(5):1125-32. https://doi.org/10.1590/S0080-62342012000500013

22. Barreto SM, Miranda JJ, Figueroa JP, Schmidt MI, Munoz S, Kuri-Morales PP, et al. Epidemiology in Latin America and the Caribbean: current situation and challenges. *Int J Epidemiol*. 2012;41(2):557-71. https://doi.org/10.1093/ije/dys017

23. International Diabetes Federation. Diabetes health economics: direct cost to the health care sector. Brussels; 2012. p.13-5.

24. Peckham R. Contagion: epidemiological models and financial crises. *J Public Health (Oxf)*. 2014;36(1):13-7. https://doi.org/10.1093/pubmed/fdt083

25. Arredondo A, Orozco E, Aviles R. Evidence on equity, governance and financing after health care reform in Mexico: lessons for Latin American countries. *Saude Soc*. 2015;24 Suppl1:158-75. https://doi.org/10.1590/S0104-12902015S01014

**Funding:** Health Sector Fund of the National Council of Science and Technology of Mexico (Project 0201306, year 2014).

**Authors’ Contribution:** Study design, first draft of the manuscript, literature review, data analysis and interpretation, and critical review: AA, EO. Data collection, statistical analysis, data analysis and interpretation, critical text review: AA, JAR, JN. Literature review, analysis and interpretation of data: AAz, JN. Data analysis, critical review of the manuscript: AA, EO, JAR, JN, AAz. All authors have approved the final version and are responsible for the content of the article.

**Conflict of Interest:** The authors disclosed no conflict of interest.